![]() Acetaminophen-D4 structure
|
Common Name | Acetaminophen-D4 | ||
---|---|---|---|---|
CAS Number | 64315-36-2 | Molecular Weight | 155.18700 | |
Density | N/A | Boiling Point | N/A | |
Molecular Formula | C8H5D4NO2 | Melting Point | 169-171°C (dec.) | |
MSDS | Chinese USA | Flash Point | 9℃ | |
Symbol |
![]() GHS07 |
Signal Word | Warning |
Name | Acetaminophen-D4 |
---|---|
Synonym | More Synonyms |
Melting Point | 169-171°C (dec.) |
---|---|
Molecular Formula | C8H5D4NO2 |
Molecular Weight | 155.18700 |
Flash Point | 9℃ |
Exact Mass | 155.08800 |
PSA | 49.33000 |
LogP | 1.42360 |
Storage condition | -20°C Freezer |
Symbol |
![]() GHS07 |
---|---|
Signal Word | Warning |
Hazard Statements | H302-H315-H319-H335 |
Precautionary Statements | P261-P305 + P351 + P338 |
Hazard Codes | Xn,T,F |
Risk Phrases | 22-36/37/38-39/23/24/25-23/24/25-11 |
Safety Phrases | 26-36-45-36/37-16-7 |
RIDADR | UN1230 - class 3 - PG 2 - Methanol, solution |
~% Acetaminophen-D4 CAS#:64315-36-2 |
Literature: Journal of Labelled Compounds and Radiopharmaceuticals, , vol. 43, # 8 p. 817 - 823 |
Precursor 1 | |
---|---|
DownStream 0 |
In vitro metabolism and drug-drug interaction potential of UTL-5g, a novel chemo- and radioprotective agent.
Drug Metab. Dispos. 42(12) , 2058-67, (2014) N-(2,4-dichlorophenyl)-5-methyl-1,2-oxazole-3-carboxamide (UTL-5g), a potential chemo- and radioprotective agent, acts as a prodrug requiring bioactivation to the active metabolite 5-methylisoxazole-3... |
|
Upcyte Human Hepatocytes: a Potent In Vitro Tool for the Prediction of Hepatic Clearance of Metabolically Stable Compounds.
Drug Metab. Dispos. 44 , 435-44, (2016) In vitro models based on primary human hepatocytes (PHH) have been advanced for clearance (CL) prediction of metabolically stable compounds, representing state-of-the-art assay systems for drug discov... |
|
Cytochrome P450 induction response in tethered spheroids as a three-dimensional human hepatocyte in vitro model.
J. Appl. Toxicol. 36 , 320-9, (2016) Cytochrome P450 (CYP) induction is a key risk factor of clinical drug-drug interactions that has to be mitigated in the early phases of drug discovery. Three-dimensional (3D) cultures of hepatocytes i... |
N-(2,3,5,6-tetradeuterio-4-hydroxyphenyl)acetamide |